Justin Thacker

Led financial strategy and operations teams through a transformative period of change and growth, partnering closely with executive leadership to align financial and operational priorities with long-term strategic goals. Oversaw accounting, budgeting, financial planning and analysis (FP&A), internal and external reporting, office and lab operations, and IT, while supporting business development, capital fundraising efforts, and cross-functional collaborations focused on maintaining fiscal discipline and IPO readiness.

Directed accounting, budgeting, financial planning and analysis, treasury, and tax functions for the clinical-stage company, driving IPO readiness initiatives and supporting strategic growth planning prior to its decision to dissolve in February 2023. Actively supported the investor relations and business development activities of the company and was a member of the Joint Development Committee and reported activity to the Company’s option holder.

Board Trustee for the Beyond Benefits Life Science Association Trust, a Department of Labor qualified Multiple Employer Welfare Arrangement (MEWA) offering employers employee benefit options by top-rated carriers.

Head of finance and accounting responsible for all financial and accounting functions. Actively supported the company’s $276M initial public offering and S-1 filings, completing two annual audits and all necessary activities within 95 days of the Company’s organization meeting. Prepared the department to operate as a public company including implementing new accounting policies and processes and systems to improve to company’s control environment.

Head of finance and accounting, responsible for building the accounting team and infrastructure from the ground up. Developed and led the corporate accounting and internal reporting, financial planning and analysis, SEC reporting, SOX compliance, cash management and planning, accounts payable, payroll, stock option administration, tax and technical accounting processes. Highly involved in the company’s $150M IPO in December 2018 and implemented the Company’s initial accounting system, payroll system, equity administration system, and expense reimbursement system, all within six months of its public offering.

Manage a team of 12 individuals, responsible for all accounting functions, including; corporate and international accounting operations, SEC reporting, SOX compliance, accounts payable, expense reimbursement, payroll, clinical trial accounting, domestic and international tax compliance, transfer pricing, technical accounting, accounts receivable/order-to-cash and cash management. Led the accounting and finance efforts for the Company's initial product launch.

Led the budgeting, financial planning and analysis, SEC reporting, SOX compliance and technical accounting functions, developing each of the functions for the newly public company. Served as the finance leader during the commercial infrastructure and strategic planning process as the Company prepared to commercialize its drug candidates.

Lead multiple areas of the finance organization, including internal and external (SEC) financial reporting, FP&A, technical accounting, stock option administration and internal controls (SOX). Instrumental in developing the finance organization as it grew from a development stage company to a commercial organization, including the revenue recognition and inventory costing policies and procedures. Supported the Company's multiple equity and debt financing's of over $330M.

Managed of a team of over 10 individuals responsible for the Company’s corporate accounting, SEC reporting, SOX compliance, accounts payable, payroll and technical accounting functions. Developed and managed the implementation of the SOX compliance program, educating numerous stakeholders throughout the organization and responsible for the adoption and implementation of SFAS 123(R) (ASC 718).